Brief: Idorsia Says To Advance Development In Autism Spectrum Disorder
Mon 06:01
BRIEF-Idorsia Says To Advance Development In Autism Spectrum Disorder Oct 26 (Reuters) - IDORSIA LTD IDIA.S:
IDORSIA TO ADVANCE DEVELOPMENT IN AUTISM SPECTRUM DISORDER
WILL THEREFORE PURSUE A NEW DEVELOPMENT PROGRAM FOR DARIDOREXANT IN ASD, WITH PROGRAM DETAILS EXPECTED IN FIRST HALF OF 2027 FOLLOWING DISCUSSIONS WITH HEALTH AUTHORITIES
IN A PHASE 2 STUDY IN PEDIATRIC INSOMNIA DISORDER, IN ADDITION TO MARKED IMPROVEMENTS IN SLEEP MEASURES, DARIDOREXANT 50 MG SHOWED AN UNEXPECTED PATTERN OF IMPROVEMENT IN AFFECT AND BEHAVIOR, COGNITION, AND DAILY ACTIVITIES IN PARTICIPANTS WITH AUTISM SPECTRUM DISORDER (ASD) OR SUBTHRESHOLD ASD CHARACTERISTICS
Source text: ID:nGNElnM21
Further company coverage: IDIA.S
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))